Clinical trial
An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
NCT00372528 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Terminated
Key facts
| NCT number | NCT00372528 |
|---|---|
| Title | An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures |
| Official title | An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164 |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | pregabalin (LYRICA) |
| Enrollment | 21 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Sep 7, 2006 |
| Last update posted | Jan 26, 2021 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: